CELESTIAL Sub-Group Discussion

Author(s):

Panelists discuss the subgroup analyses from the CELESTIAL trial, focusing on treatment outcomes for specific patient populations with previously treated hepatocellular carcinoma.

EP: 1.Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP: 2.Treatment Decisions Based on BLCL Stage

EP: 3.Current Treatment in First Line – IO + TKI or IO + IO

EP: 4.Use of monotherapy (IO or TKI) or localized treatment in First Line

EP: 8.Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

EP: 9.ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

EP: 10.Choosing Second-Line Therapies: Considering First Line Therapy Received

EP: 11.Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

Now Viewing

EP: 12.CELESTIAL Sub-Group Discussion

Video content above is prompted by the following:

Dr Alese: Please discuss the data surrounding about treatment with cabozantinib for previously treated hepatocellular carcinomaHCC from the CELESTIAL trial.
• Primary trial results – (Abou-Alfa G, et al. N Eng J Med. 2018)
• Child-Pugh class B subgroup analysis – (El-Khoueiry AB, et al. BMC Cancer. 2022)
• Prior immuno-oncologyIO subgroup analysis – (Wong JSL, et al. J Clin Oncol. 2021)